Evidence map›Paper›PMID 30693469›Full record

Observational studyThe British journal of dermatology2019

Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.

E Chacón-Solano, C León, F Díaz, F García-García, M García, M J Escámez, S Guerrero-Aspizua, C J Conti, Á Mencía, L Martínez-Santamaría and 11 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Progress in skin gene therapy: From the inside and out.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. The Role of Fibroblasts in Dystrophic Epidermolysis Bullosa Pathogenesis and Current Treatment Approaches.JID innovations : skin science from molecules to population health · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Signatures of Dermal Fibroblasts from RDEB Pediatric Patients.International journal of molecular sciences · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 1 country.

E Chacón-SolanoDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
C LeónDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
F DíazDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
F García-GarcíaBioinformatics and Biostatistics Unit, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
M GarcíaDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
M J EscámezDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
S Guerrero-AspizuaDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
C J ContiDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.ORCID 0000-0003-4753-0722
Á MencíaDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
L Martínez-SantamaríaDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
S LlamesRegenerative Medicine and Tissue Engineering Group, Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
M PévidaTissue Engineering Unit, Centro Comunitario Sangre y Tejidos (CCST), Oviedo, Spain.
J Carbonell-CaballeroDepartment of Computational Genomics, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
J A Puig-ButilléMelanoma Unit, Hospital Clinic & IDIBAPS (Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer), CIBERER (U726), Universitat de Barcelona, Barcelona, Spain.
R MasedaDepartment of Pediatric Dermatology, La Paz Hospital, Madrid, Spain.
S PuigMelanoma Unit, Hospital Clinic & IDIBAPS (Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer), CIBERER (U726), Universitat de Barcelona, Barcelona, Spain.
R de LucasDepartment of Pediatric Dermatology, La Paz Hospital, Madrid, Spain.
E BaselgaDepartment of Pediatric Dermatology, Santa Creu I Sant Pau Hospital, Barcelona, Spain.
F LarcherDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.ORCID 0000-0002-6771-3561
J DopazoClinical Bioinformatics Area, Fundación Progreso y Salud, CDCA, Hospital Virgen del Rocío, Sevilla, Spain.
M Del RíoDepartment of Bioengineering, Universidad Carlos III de Madrid, Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases · ESHospital Universitario Fundación Jiménez Díaz · ESCentro de Investigación Biomédica en Red · ESCentro de Investigacion Principe Felipe · ESHospital Universitario La Paz · ESFundación Progreso y Salud · ESHospital de Sant Pau · ES

Funding

Catalan Government AGAUR 2014_SGR_603Comunidad de Madrid AvanCell-CM S2017/BMD-3692European Union H2020-INFRADEV-1-2015-1 / ELIXIR-EXCELERATE-ref.67European Union HEALTH-F2-2011-261392Instituto de Salud Carlos III PI14/00931Instituto de Salud Carlos III PI15/00716Instituto de Salud Carlos III PI15/00956Instituto de Salud Carlos III PI17/01747Instituto de Salud Carlos III PT13/0001/0007Instituto de Salud Carlos III PT17/0009/0006Ministerio de Economía y Competitividad SAF2013-43475RMinisterio de Economía y Competitividad SAF2017-86810-RMinisterio de Economía y Competitividad SAF2017-88908-R
6 · The paper itself

Abstract

backgroundRecessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and xeroderma pigmentosum complementation group C (XPC) are three cancer-prone genodermatoses whose causal genetic mutations cannot fully explain, on their own, the array of associated phenotypic manifestations. Recent evidence highlights the role of the stromal microenvironment in the pathology of these disorders.

objectivesTo investigate, by means of comparative gene expression analysis, the role played by dermal fibroblasts in the pathogenesis of RDEB, KS and XPC.

methodsWe conducted RNA-Seq analysis, which included a thorough examination of the differentially expressed genes, a functional enrichment analysis and a description of affected signalling circuits. Transcriptomic data were validated at the protein level in cell cultures, serum samples and skin biopsies.

resultsInterdisease comparisons against control fibroblasts revealed a unifying signature of 186 differentially expressed genes and four signalling pathways in the three genodermatoses. Remarkably, some of the uncovered expression changes suggest a synthetic fibroblast phenotype characterized by the aberrant expression of extracellular matrix (ECM) proteins. Western blot and immunofluorescence in situ analyses validated the RNA-Seq data. In addition, enzyme-linked immunosorbent assay revealed increased circulating levels of periostin in patients with RDEB.

conclusionsOur results suggest that the different causal genetic defects converge into common changes in gene expression, possibly due to injury-sensitive events. These, in turn, trigger a cascade of reactions involving abnormal ECM deposition and underexpression of antioxidant enzymes. The elucidated expression signature provides new potential biomarkers and common therapeutic targets in RDEB, XPC and KS. What's already known about this topic? Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and xeroderma pigmentosum complementation group C (XPC) are three genodermatoses with high predisposition to cancer development. Although their causal genetic mutations mainly affect epithelia, the dermal microenvironment likely contributes to the physiopathology of these disorders. What does this study add? We disclose a large overlapping transcription profile between XPC, KS and RDEB fibroblasts that points towards an activated phenotype with high matrix-synthetic capacity. This common signature seems to be independent of the primary causal deficiency, but reflects an underlying derangement of the extracellular matrix via transforming growth factor-β signalling activation and oxidative state imbalance. What is the translational message? This study broadens the current knowledge about the pathology of these diseases and highlights new targets and biomarkers for effective therapeutic intervention. It is suggested that high levels of circulating periostin could represent a potential biomarker in RDEB.

Indexed as

AdolescentAdultBiopsyBlisterCase-Control StudiesCells, CulturedChildChild, PreschoolEpidermolysis BullosaEpidermolysis Bullosa DystrophicaExtracellular MatrixExtracellular Matrix ProteinsFemaleFibroblastsFibrosisGene Expression RegulationExtracellular Matrix Proteins

Identifiers

PMID30693469
PMCPMC6850467
OpenAlexW2914146213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.